Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and b...
- Autores
- Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul
- Año de publicación
- 2011
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC.
Fil: Vignaduzzo, Silvana Edit. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Castellano, Patricia Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Kaufman, Teodoro Saul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina - Materia
-
EXPERIMENTAL DESIGN
HPLC-DAD
HPLC-UV
RP-HPLC
TRIPLE COMBINATION
VALIDATION - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/127120
Ver los metadatos del registro completo
id |
CONICETDig_3cc37c62dd1b0795efa6d932392323ab |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/127120 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associationsVignaduzzo, Silvana EditCastellano, Patricia MargaritaKaufman, Teodoro SaulEXPERIMENTAL DESIGNHPLC-DADHPLC-UVRP-HPLCTRIPLE COMBINATIONVALIDATIONhttps://purl.org/becyt/ford/1.4https://purl.org/becyt/ford/1The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC.Fil: Vignaduzzo, Silvana Edit. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Castellano, Patricia Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Kaufman, Teodoro Saul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaTaylor & Francis2011-11-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/127120Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul; Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations; Taylor & Francis; Journal of Liquid Chromatography and Related Technologies; 34; 19; 18-11-2011; 2383-23951082-6076CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/10826076.2011.591020info:eu-repo/semantics/altIdentifier/doi/10.1080/10826076.2011.591020info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:46:41Zoai:ri.conicet.gov.ar:11336/127120instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:46:41.34CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations |
title |
Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations |
spellingShingle |
Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations Vignaduzzo, Silvana Edit EXPERIMENTAL DESIGN HPLC-DAD HPLC-UV RP-HPLC TRIPLE COMBINATION VALIDATION |
title_short |
Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations |
title_full |
Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations |
title_fullStr |
Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations |
title_full_unstemmed |
Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations |
title_sort |
Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations |
dc.creator.none.fl_str_mv |
Vignaduzzo, Silvana Edit Castellano, Patricia Margarita Kaufman, Teodoro Saul |
author |
Vignaduzzo, Silvana Edit |
author_facet |
Vignaduzzo, Silvana Edit Castellano, Patricia Margarita Kaufman, Teodoro Saul |
author_role |
author |
author2 |
Castellano, Patricia Margarita Kaufman, Teodoro Saul |
author2_role |
author author |
dc.subject.none.fl_str_mv |
EXPERIMENTAL DESIGN HPLC-DAD HPLC-UV RP-HPLC TRIPLE COMBINATION VALIDATION |
topic |
EXPERIMENTAL DESIGN HPLC-DAD HPLC-UV RP-HPLC TRIPLE COMBINATION VALIDATION |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.4 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC. Fil: Vignaduzzo, Silvana Edit. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina Fil: Castellano, Patricia Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina Fil: Kaufman, Teodoro Saul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina |
description |
The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-11-18 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/127120 Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul; Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations; Taylor & Francis; Journal of Liquid Chromatography and Related Technologies; 34; 19; 18-11-2011; 2383-2395 1082-6076 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/127120 |
identifier_str_mv |
Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul; Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations; Taylor & Francis; Journal of Liquid Chromatography and Related Technologies; 34; 19; 18-11-2011; 2383-2395 1082-6076 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/10826076.2011.591020 info:eu-repo/semantics/altIdentifier/doi/10.1080/10826076.2011.591020 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Taylor & Francis |
publisher.none.fl_str_mv |
Taylor & Francis |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1846083563208835072 |
score |
13.22299 |